Literature DB >> 28394371

Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.

S W Wong1, D Larivee2, M Warner3, K A Sprague2,3, T Fogaren2,3, R L Comenzo2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28394371     DOI： 10.1038/bmt.2017.47

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; Dennis A Gastineau
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

2.  Systemic light chain amyloidosis: an update for treating physicians.

Authors:  Giampaolo Merlini; Ashutosh D Wechalekar; Giovanni Palladini
Journal:  Blood       Date:  2013-05-13       Impact factor: 22.113

Review 3.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Authors:  R L Comenzo; D Reece; G Palladini; D Seldin; V Sanchorawala; H Landau; R Falk; K Wells; A Solomon; A Wechalekar; J Zonder; A Dispenzieri; M Gertz; H Streicher; M Skinner; R A Kyle; G Merlini
Journal:  Leukemia       Date:  2012-04-05       Impact factor: 11.528

Review 4.  Autologous stem cell transplantation for primary systemic amyloidosis.

Authors:  Raymond L Comenzo; Morie A Gertz
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.

Authors:  Umit Tapan; David C Seldin; Kathleen T Finn; Salli Fennessey; Anthony Shelton; Jerome B Zeldis; Vaishali Sanchorawala
Journal:  Blood       Date:  2010-12-02       Impact factor: 22.113

6.  Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Anita D'Souza; Angela Dispenzieri; Baldeep Wirk; Mei-Jie Zhang; Jiaxing Huang; Morie A Gertz; Robert A Kyle; Shaji Kumar; Raymond L Comenzo; Robert Peter Gale; Hillard M Lazarus; Bipin N Savani; Robert F Cornell; Brendan M Weiss; Dan T Vogl; César O Freytes; Emma C Scott; Heather J Landau; Jan S Moreb; Luciano J Costa; Muthalagu Ramanathan; Natalie S Callander; Rammurti T Kamble; Richard F Olsson; Siddhartha Ganguly; Taiga Nishihori; Tamila L Kindwall-Keller; William A Wood; Tomer M Mark; Parameswaran Hari
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

7.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

8.  Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.

Authors:  R F Cornell; X Zhong; C Arce-Lara; E Atallah; L Blust; W R Drobyski; T S Fenske; M C Pasquini; J D Rizzo; W Saber; P N Hari
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

9.  Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Authors:  Tilmann Bochtler; Ute Hegenbart; Christina Kunz; Axel Benner; Christoph Kimmich; Anja Seckinger; Dirk Hose; Hartmut Goldschmidt; Martin Granzow; Peter Dreger; Anthony D Ho; Anna Jauch; Stefan O Schönland
Journal:  Blood       Date:  2016-06-02       Impact factor: 22.113

10.  Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.

Authors:  H Landau; M Smith; C Landry; J F Chou; S M Devlin; H Hassoun; C Bello; S Giralt; R L Comenzo
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528
View more
  1 in total

Review 1.  Systemic amyloidosis: moving into the spotlight.

Authors:  Oliver C Cohen; Ashutosh D Wechalekar
Journal:  Leukemia       Date:  2020-04-09       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.